Novo Nordisk A/S
NVO62.550USD
-4.590-6.84%
收盤 04/04, 16:00（美東）報價延遲15分鐘
210.54B總市值
14.37本益比TTM
關於 Novo Nordisk A/S 公司
Novo Nordisk A/S 是一家從事糖尿病護理的全球醫療保健公司。該公司還從事醫藥產品的發現、開發、製造和營銷。該公司通過兩個業務部門運營：糖尿病和肥胖護理以及生物製藥。該公司的糖尿病和肥胖護理部門涵蓋胰島素、GLP-1、其他蛋白質相關產品（如胰高血糖素）、蛋白質相關輸送系統和針頭以及口服抗糖尿病藥物。該公司的生物製藥部門涵蓋血友病護理、生長激素治療和激素替代療法等治療領域。該公司還提供用於治療肥胖症的 Saxenda 產品。它提供一系列產品，包括 NovoLog/NovoRapid；NovoLog Mix/NovoMix；Prandin/NovoNorm；NovoSeven；Norditropin 和 Vagifem。截至 2016 年 12 月 31 日，該公司的產品銷往 180 多個國家。其區域結構由兩個商業部門組成：北美和國際運營。
公司簡介
公司代碼NVO
公司名稱Novo Nordisk A/S
上市日期May 17, 1974
成立日期1931
CEOMr. Lars Fruergaard Joergensen
員工數量76302
證券類型Ordinary Share
年結日May 17
公司地址Novo Alle 1
城市BAGSVAERD
上市交易所The Toronto Stock Exchange
國家Denmark
郵編2880
電話4544448888
網址https://www.novonordisk.com/
公司代碼NVO
上市日期May 17, 1974
成立日期1931
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
,
,
Executive Vice President - Quality, IT & Environmental Affairs
Executive Vice President - Quality, IT & Environmental Affairs
--
--
Mr. Jacob Martin Wiborg Rode
Mr. Jacob Martin Wiborg Rode
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Helge Lund
Mr. Helge Lund
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. David Moore
Mr. David Moore
Executive Vice President - US Operations and Business Development
Executive Vice President - US Operations and Business Development
--
--
Mr. Karsten Munk Knudsen
Mr. Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Thomas Rantzau
Mr. Thomas Rantzau
Director, Employee Representative
Director, Employee Representative
--
--
Ms. Tania Sabroe
Ms. Tania Sabroe
Executive Vice President - Global People, Organisation and Communication
Executive Vice President - Global People, Organisation and Communication
--
--
Dr. Martin Holst Lange
Dr. Martin Holst Lange
Executive Vice President - Development
Executive Vice President - Development
--
--
Mr. Andreas Fibig
Mr. Andreas Fibig
Independent Director
Independent Director
--
--
Dr. Sylvie L. Gregoire, Pharm.D.
Dr. Sylvie L. Gregoire, Pharm.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
,
,
Executive Vice President - Quality, IT & Environmental Affairs
Executive Vice President - Quality, IT & Environmental Affairs
--
--
Mr. Jacob Martin Wiborg Rode
Mr. Jacob Martin Wiborg Rode
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Helge Lund
Mr. Helge Lund
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. David Moore
Mr. David Moore
Executive Vice President - US Operations and Business Development
Executive Vice President - US Operations and Business Development
--
--
Mr. Karsten Munk Knudsen
Mr. Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Thomas Rantzau
Mr. Thomas Rantzau
Director, Employee Representative
Director, Employee Representative
--
--
收入明細
單位: USD更新時間: 4 小時前
單位: USD更新時間: 4 小時前
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Total GLP-1
21.63B
51.35%
Obesity (Saxenda®)
9.45B
22.43%
Long-acting insulin
2.77B
6.58%
Fast-acting insulin
2.69B
6.38%
Rare blood disorders
1.76B
4.18%
Other
3.83B
9.08%
地區USD
名稱
營收
佔比
USA
24.28B
57.64%
EMEA
8.76B
20.80%
Rest of World
4.83B
11.48%
Region China
2.68B
6.37%
Canada
1.56B
3.71%
業務
地區
業務USD
名稱
營收
佔比
Total GLP-1
21.63B
51.35%
Obesity (Saxenda®)
9.45B
22.43%
Long-acting insulin
2.77B
6.58%
Fast-acting insulin
2.69B
6.38%
Rare blood disorders
1.76B
4.18%
Other
3.83B
9.08%
股東統計
更新時間: 3月11日 週二
更新時間: 3月11日 週二
持股股東
股東類型
持股股東
股東統計
佔比
Jennison Associates LLC
0.59%
GQG Partners, LLC
0.39%
Fisher Investments
0.38%
Loomis, Sayles & Company, L.P.
0.34%
Fayez Sarofim & Co.
0.34%
Other
97.96%
持股股東
股東統計
佔比
Jennison Associates LLC
0.59%
GQG Partners, LLC
0.39%
Fisher Investments
0.38%
Loomis, Sayles & Company, L.P.
0.34%
Fayez Sarofim & Co.
0.34%
Other
97.96%
股東類型
股東統計
佔比
Investment Advisor
5.20%
Investment Advisor/Hedge Fund
2.92%
Research Firm
0.82%
Hedge Fund
0.63%
Pension Fund
0.28%
Insurance Company
0.21%
Bank and Trust
0.17%
Family Office
0.02%
Family Office
0.02%
Other
89.73%
機構持股
更新時間: 2月20日 週四
更新時間: 2月20日 週四
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
2667
350.24M
10.41%
+3.15M
2024Q4
2676
348.53M
10.35%
+330.19K
2024Q3
2529
339.29M
10.15%
-6.04M
2024Q2
2456
341.24M
10.21%
+6.87M
2024Q1
2291
330.25M
9.75%
+10.89M
2023Q4
2037
314.57M
9.30%
+1.47M
2023Q3
1826
307.14M
8.91%
+4.22M
2023Q2
1692
293.83M
8.50%
+768.69K
2023Q1
1603
284.38M
8.30%
-15.92M
2022Q4
1498
293.73M
8.57%
+2.21M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Jennison Associates LLC
19.94M
0.59%
-251.15K
-1.24%
Dec 31, 2024
GQG Partners, LLC
12.99M
0.39%
+5.56M
+74.70%
Dec 31, 2024
Fisher Investments
12.64M
0.38%
-664.99K
-5.00%
Dec 31, 2024
Loomis, Sayles & Company, L.P.
11.57M
0.34%
+2.95M
+34.18%
Dec 31, 2024
Fayez Sarofim & Co.
11.38M
0.34%
-832.64K
-6.82%
Dec 31, 2024
Fidelity Management & Research Company LLC
9.89M
0.29%
-7.78M
-44.05%
Dec 31, 2024
Managed Account Advisors LLC
9.39M
0.28%
+1.11M
+13.43%
Dec 31, 2024
Folketrygdfondet
8.90M
0.26%
+40.31K
+0.45%
Dec 31, 2024
Renaissance Technologies LLC
8.31M
0.25%
+123.68K
+1.51%
Dec 31, 2024
Capital International Investors
6.75M
0.2%
-204.59K
-2.94%
Dec 31, 2024
查看更多
持股ETF
更新時間: 17 小時前
更新時間: 17 小時前
機構名稱
佔比
Novo Nordisk A/S (B Shares) ADRhedged
100%
Roundhill GLP-1 & Weight Loss ETF
15.18%
Amplify Weight Loss Drug & Treatment ETF
13.08%
VanEck Pharmaceutical ETF
4.86%
iShares Long-Term US Equity Active ETF
4.59%
AdvisorShares Gerber Kawasaki ETF
4.03%
TrueShares Technology, AI & Deep Learning ETF
3.12%
Clockwise Core Equity & Innovation ETF
2.63%
PGIM Jennison Better Future ETF
2.37%
SP Funds S&P World (ex-US) ETF
2.34%
查看更多
Novo Nordisk A/S (B Shares) ADRhedged
佔比100%
Roundhill GLP-1 & Weight Loss ETF
佔比15.18%
Amplify Weight Loss Drug & Treatment ETF
佔比13.08%
VanEck Pharmaceutical ETF
佔比4.86%
iShares Long-Term US Equity Active ETF
佔比4.59%
AdvisorShares Gerber Kawasaki ETF
佔比4.03%
TrueShares Technology, AI & Deep Learning ETF
佔比3.12%
Clockwise Core Equity & Innovation ETF
佔比2.63%
PGIM Jennison Better Future ETF
佔比2.37%
SP Funds S&P World (ex-US) ETF
佔比2.34%
分紅派息
近5年累計派現
21.09B
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Aug 06, 2024
NVO.NB Final Cash Dividend of gross USD 0.516902 paid on Aug 26, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Aug 26, 2024
Aug 16, 2024
Jan 31, 2024
NVO.NB Interim Cash Dividend of gross USD 0.929335 paid on Apr 02, 2024 going ex on Mar 22, 2024
Mar 25, 2024
Apr 02, 2024
Mar 22, 2024
Aug 10, 2023
NVO.NB Final Cash Dividend of gross USD 0.876339 paid on Aug 29, 2023 going ex on Aug 18, 2023
Aug 21, 2023
Aug 29, 2023
Aug 18, 2023
Feb 02, 2023
NVO.NB Interim Cash Dividend of gross USD 1.180581 paid on Apr 04, 2023 going ex on Mar 24, 2023
Mar 27, 2023
Apr 04, 2023
Mar 24, 2023
Aug 04, 2022
NVO.NB Final Cash Dividend of gross USD 0.577745 paid on Aug 23, 2022 going ex on Aug 12, 2022
Aug 15, 2022
Aug 23, 2022
Aug 12, 2022
Mar 02, 2022
NVO.NB Interim Cash Dividend of gross USD 1.022424 paid on Apr 05, 2022 going ex on Mar 25, 2022
Mar 28, 2022
Apr 05, 2022
Mar 25, 2022
Aug 05, 2021
NVO.NB Final Cash Dividend of gross USD 0.550289 paid on Aug 25, 2021 going ex on Aug 16, 2021
Aug 17, 2021
Aug 25, 2021
Aug 16, 2021
Feb 22, 2021
NVO.NB Interim Cash Dividend of gross USD 0.922122 paid on Apr 07, 2021 going ex on Mar 26, 2021
Mar 29, 2021
Apr 07, 2021
Mar 26, 2021
Aug 06, 2020
NVO.NB Final Cash Dividend of gross USD 0.517777 paid on Aug 25, 2020 going ex on Aug 14, 2020
Aug 17, 2020
Aug 25, 2020
Aug 14, 2020
Feb 06, 2020
NVO.NB Interim Cash Dividend of gross USD 0.782605 paid on Apr 07, 2020 going ex on Mar 27, 2020
Mar 30, 2020
Apr 07, 2020
Mar 27, 2020
拆合股
公告日期
類型
比率
Aug 14, 2023
Split
1>2
公告日期
類型
比率
Aug 14, 2023
Split
1>2